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A doxorubicin derivate, SA-17, that carries a squaric acid amide ester moiety at the carbohydrate (-L-
daunosaminyl) group was identified as a selective inhibitor of in vitro dengue virus (DENV) serotype 2
replication (50% effective concentration [EC50] 0.34 0.20 g/ml [0.52 0.31 M]). SA-17 is markedly less
cytostatic than the parent compound, resulting in a selectivity index value of 100. SA-17 also inhibits yellow
fever virus 17D (YFV-17D) replication (EC50  3.1  1.0 g/ml [4.8  1.5 M]), although less efficiently than
DENV replication, but proved inactive against a variety of enveloped and nonenveloped viruses. SA-17 inhibits
in vitro flavivirus replication in a dose-dependent manner, as was assessed by virus yield reduction assays and
quantification of viral RNA by means of real-time quantitative reverse transcriptase PCR (RT-qPCR) (2 to
3 log reduction). The anti-DENV activity was confirmed using a Renilla luciferase-expressing dengue reporter
virus. Time-of-drug-addition studies revealed that SA-17 acts at the very early stages of the viral replication
cycle (i.e., virus attachment and/or virus entry). This observation was corroborated by the observation that
SA-17, unlike the nucleoside analogue ribavirin, does not inhibit the replication of DENV subgenomic repli-
cons. Preincubation of high-titer stocks of DENV or YFV-17D with >5 g/ml SA-17 resulted in 100% inhibition
of viral infectivity (>3 log reduction). SA-17, however, did not prove virucidal.
Dengue virus (DENV), of which four serotypes (DENV-1,
-2, -3, and -4) are known, and yellow fever virus (YFV) belong
to the mosquito-borne cluster of the genus Flavivirus (family
Flaviviridae) (25). According to the World Health Organiza-
tion (WHO), 2.5 billion people, of whom 1 billion are children,
are at risk of DENV infection (72). An estimated 50 to 100
million cases of dengue fever, half a million cases of severe
dengue disease (i.e., dengue hemorrhagic fever [DHF] and
dengue shock syndrome [DSS]), and more than 20,000 deaths
occur worldwide each year (69, 72). Every year, increasing
numbers of dengue outbreaks/cases are reported. Travelers
visiting areas where DENV is endemic (a steadily increasing
number) are also at risk of exposure to dengue (70). Dengue
fever has been diagnosed in increasing numbers of febrile
travelers returning from the tropics, ranging from 2% in the
early 1990s to 16% or more recently (4, 5, 33, 59). Due to the
nonspecific and self-limiting nature of the milder infections,
these data very likely represent an underestimation of the true
incidence. In addition, dengue fever represents an emerging
problem for troops as well as personnel of nongovernmental
organizations (NGOs) deployed in tropical countries where
dengue is endemic (49). In Africa, 33 countries, comprising a
total population of nearly 510 million people, are at risk of
YFV infection (71). Yellow fever is also endemic in South
American countries and in several Caribbean islands. Annu-
ally, 200,000 estimated cases of yellow fever, with 30,000
deaths, occur (8, 71). The number of yellow fever epidemics is
rising, and more countries are reporting cases. Besides vector
control measures, vaccination with the attenuated 17D strain is
the most important weapon in the fight against yellow fever.
This vaccine has an outstanding safety profile and is highly
effective. Mass vaccination campaigns between 1933 and 1961
resulted in the gradual disappearance of the disease. However,
these programs have lapsed over the years, leading to a resur-
gence of yellow fever epidemics.
To prevent and/or control dengue disease, the only currently
available methods are mosquito control strategies. The devel-
opment of effective and safe dengue virus vaccines has proven
to be a true challenge, mostly because of the link between
secondary dengue virus infection (i.e., reinfection with a dif-
ferent serotype) and severe clinical disease (DHF) (15, 35, 60).
Recovery from an infection by one serotype provides long-
lasting immunity against that particular serotype but confers
only partial and transient protection against a subsequent in-
fection by any of the other three serotypes. In secondary in-
fections, antibodies against the first serotype appear to en-
hance infection with the second serotype (a phenomenon
known as antibody-dependent enhancement of infection), re-
sulting in higher peak viral titers. Higher viral loads have been
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correlated with more severe dengue disease (32, 64, 67). It is of
utmost importance to have better means (other than mosquito
control efforts and, hopefully within a few years, vaccines) at
hand to control dengue (and yellow fever) outbreaks. More-
over, it would also be important to have potent and selective
inhibitors of YFV replication and other flaviviruses (such as
the Japanese encephalitis virus [JEV], the tick-borne enceph-
alitis virus [TBEVR], and the West Nile virus [WNV]) at hand
for the treatment of life-threatening infections caused by these
viruses. Recently, a number of inhibitors of DENV and/or
other flaviviruses have been reported. These include nucleo-
side/nucleotide analogues targeting either the polymerase (10,
29, 37, 53, 74) or the protease of the virus (63). A few mole-
cules have been shown to inhibit the early stages of the dengue
virus replication cycle (51, 66). Here, we report on the activity
against DENV and some other flaviviruses of SA-17, a derivate
of the anthracycline antibiotic doxorubicin. The parent com-
pound doxorubicin was earlier shown to be active against a
variety of other viruses, such as HIV and herpes simplex virus
(3, 21, 22, 48). SA-17 inhibits virus replication by targeting the
very early stages of the viral replication cycle.
MATERIALS AND METHODS
Compounds. Ribavirin or 1-(-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxam-
ide (Virazole; RBV) was purchased from ICN Pharmaceuticals (Costa Mesa,
CA). Doxorubicin or (8S,10S)-10-(4-amino-5-hydroxy-6-methyl-tetrahydro-2H-
pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-etra-
hydrotetracene-5,12-dione (trade name Adriamycin) was obtained from Sigma-
Aldrich (Bornem, Belgium). The doxorubicin derivates SA-3, SA-11, and SA-17
(Table 1) were synthesized as reported elsewhere (61, 62).
TABLE 1. Structural formulae and effect of doxorubicin and analogues on DENV-2 NGC and YFV-17D replicationa
Name Structure Mol wt EC50 (DENV) EC50 (YFV) CC50
Doxorubicin 544 0.67  0.37 (1.2  0.68) 0.32  0.01 (0.59  0.02) 13  0.7 (24  1.3)
SA-3 637 100 (157) 100 (157) 22  1.6 (35  2.5)
SA-11 623 100 (161) 100 (161) 0.2 (0.32)
SA-17 653 0.34  0.20 (0.52  0.31) 3.1  1.0 (4.8  1.5) 28  2.7 (43  4.1)
a EC50 and CC50 data are expressed in g/ml (M in parentheses) and are mean values for at least two independent experiments.
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Cells and replicons. African green monkey kidney cells (Vero-B cells; ATCC
CCL-81) were grown in minimum essential medium (MEM; Invitrogen, Merel-
beke, Belgium) supplemented with 10% heat-inactivated fetal calf serum (FCS;
Integro, Zaandam, Netherlands), 0.075% sodium bicarbonate (Invitrogen), and
2 mM L-glutamine (Invitrogen) at 37°C and in a 5% CO2 incubator. Antiviral
assays using Vero-B cells were performed in assay medium (MEM supplemented
with 2% FCS, 0.075% sodium bicarbonate, and 2 mM L-glutamine). C6/36
mosquito cells (from Aedes albopictus; ATCC CRL-1660) were grown in MEM
supplemented with 8% FCS, 2 mM L-glutamine, 0.01 M HEPES buffer (Invitro-
gen), 1 nonessential amino acids (Invitrogen), and penicillin (100 U/ml)-strep-
tomycin (100 g/ml) solution (Invitrogen) at 28°C in the absence of 5% CO2.
Baby hamster kidney (BHK-21; ATCC CCL10) cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen) supplemented with 10% FCS
and 1 mM sodium pyruvate (Invitrogen) at 37°C and 5% CO2, and assays using
these cells were performed in DMEM supplemented with 2% FCS and 1 mM
sodium pyruvate. BHK-21 cells harboring the subgenomic dengue virus replicon
dCprMEPAC2NS3lucNS3 (derived from the dengue virus replicon construct
pDENCprME-PAC2A [23]), in which an antibiotic selection cassette encoding
the puromycin N-acetyltransferase (PAC) together with the firefly luciferase
expression cassette was inserted upstream of the nonstructural (NS) genes (see
Fig. 5A), will be referred to as BHK-Rep-Pac-LUC cells. BHK-Rep-Pac-LUC
cells were cultured as the parental BHK-21 cells, with the exception that 3.3
g/ml of puromycin was added to the culture medium (Sigma-Aldrich, Bornem,
Belgium). Puromycin was omitted from the culture medium in antiviral assays.
Viruses. Modoc virus (MODV) strain M544 (ATCC VR415) was propagated
in BHK-21 cells. The YFV-17D vaccine strain (Stamaril) (Aventis Pasteur MSD,
Brussels, Belgium) was passaged once in Vero-B cells to prepare a working virus
stock and stored at 	80°C until further use. DENV serotype 2 New Guinea C
(NGC) strain (kindly provided by V. Deubel [formerly at Institut Pasteur, Lyon,
France]) was cultivated in either Vero-B or C6/36 mosquito cells. Dengue virus
serotype 1 Djibouti strain D1/H/IMTSSA/98/606 (GenBank accession number
AF298808), dengue virus serotype 3 strain H87 prototype (c93130), and dengue
virus serotype 4 strain Dak HD 34 460 (only partial, unpublished sequences
available) were propagated in C6/36 mosquito cells. All four DENV serotypes
that were passaged in C6/36 mosquito cells were titrated by means of a flow
cytometry-based assay to calculate the number of infectious units (26) prior to
use. The construction of an infectious, full-length dengue virus (DENV-2 16681),
in which a Renilla luciferase expression cassette under the translational control of
the encephalomyocarditis virus internal ribosome entry site (EMCV IRES) was
inserted upstream of the 3
 untranslated (UTR) region (see Fig. 3A), was
reported earlier (42). In the current study, this virus is referred to as “dengue
reporter virus.” All work using infectious Japanese encephalitis virus (JEV)
strain SA-14, tick-borne encephalitis virus (TBEV) strain Oshima, and West Nile
virus (WNV) strain NY99 was carried out in a biosafety level 3 laboratory. The
batches of viral inoculum (JEV, TBEV, and WNV) were prepared by culturing
virus twice on Vero cells in MEM supplemented with 7% FCS, 2 mM L-glu-
tamine, and penicillin-streptomycin. Finally, cell culture supernatants were col-
lected and frozen at 	80°C in 50 mM HEPES. JEV, TBEV, and WNV were
titrated by performing a plaque assay on Vero or BHK-21 cells.
Cytotoxic and cytostatic assay in Vero-B cells. Potential cytotoxic effects of the
compounds were evaluated in uninfected quiescent Vero-B cells. Cells were
seeded at 1  104 cells/well in a 96-well plate in the presence of 2-fold serial
dilutions (ranging from 0.20 to 100 g/ml) of either SA-17 (0.30 to 153 M) or
doxorubicin (0.36 to 184 M) and incubated for 1 week. After 1 week, culture
medium was discarded, and 100 l 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium/phenazinemethosulfate (MTS/
PMS; Promega, Leiden, Netherlands) in phosphate-buffered saline (PBS) was
added to each well. Following a 2-hour incubation period at 37°C, the optical
density (OD) was determined at 498 nm. Cytotoxic activity was calculated using
the following formula: % CPE  100  (ODCompound/ODCC), where CPE is the
cytopathic effect and ODCompound and ODCC correspond to the optical density at
498 nm of the uninfected cell cultures treated with compound and that of
uninfected, untreated cell cultures, respectively. The 50% cytotoxic concentra-
tion (CC50; i.e., the concentration that reduces the total cell number by 50%) was
calculated using linear interpolation. The cytostatic effect was assessed on expo-
nentially growing Vero-B cells that were cultured for 20 consecutive passages.
During each passage, cells were seeded at a fixed number (3 105 cells in 25-cm2
tissue culture flasks) in the absence/presence of either 1 or 10 g/ml of com-
pound. Cells were allowed to proliferate for 7 days after which they were
trypsinized and the cell number was determined using a Coulter Counter. Sub-
sequently, 3  105 cells were seeded per flask and were further cultured in the
presence of the drug until reaching passage 20.
Antiviral assay. To each well of a 96-well plate, 100 l of culture medium
containing 100 50% cell culture infectious doses (i.e., CCID50) of virus was
added to each well, after which 2-fold serial dilutions of the compounds and 100
l cell suspension (2.5  104 Vero-B or BHK-21) were added. After a 1-week
incubation, culture medium was discarded, and 100 l MTS/PMS (Promega) in
PBS was added to each well. Following a 2-hour incubation period at 37°C, the
optical density was determined at 498 nm (Safire; Tecan, Mechelen, Belgium),
and the percentage of the CPE was calculated as follows: % CPE  100 
([ODVirusCompound 	 ODVC]/[ODCC 	 ODVC]). In this formula, ODCC rep-
resents the optical density of the uninfected untreated cells, whereas ODVC and
ODVirusCompound represent the optical densities of infected, untreated cells and
virus-infected cells that were treated with a given concentration of compound,
respectively. The 50% effective concentration (EC50), which is defined as the
compound concentration that is required to inhibit the virus-induced CPE by
50%, was determined using logarithmic interpolation. Ribavirin was included as
a reference compound. Each experiment was carried out at least in quadrupli-
cate, and two independent experiments were carried out.
Antiviral assays for coxsackievirus B3 (CVB3; Nancy strain), herpes simplex
virus type 1 (KOS), HIV-1, and influenza A virus H2N2 (A2 Japan/305/57) were
carried out as described earlier (6, 7, 12, 56, 76).
Antiviral assay using dengue reporter virus. One day prior to infection, 1 
104 BHK-21 cells were seeded per well in a tissue culture-treated white-view
96-well plate (Perkin-Elmer, Boston, MA). The next day, cells were infected with
2  105 PFU/well of dengue reporter virus in the absence or presence of 0.1, 1,
or 10 g/ml (0.15, 1.5 or 15 M) of SA-17. The viral inoculum was removed 1 h
later, and cells were rinsed three times with PBS. Luciferase activity was mea-
sured at 10, 24, 48, and 72 h postinfection (p.i.) using the Renilla luciferase assay
system according to the manufacturer’s protocol (Promega). Counts were de-
tected using a Safire plate reader (Tecan, Mechelen, Belgium).
Virus yield assay. DENV-2 NGC or YFV-17D (100 CCID50/well) was added
to a 96-well plate, after which 2-fold serial dilutions of the compounds and 100-l
cell suspensions (5  104 Vero-B or BHK-21) were added. Four hours later,
culture medium was carefully removed and the monolayers were washed three
times with assay medium to remove residual, nonadsorbed virus. Cells were
cultivated with fresh assay medium containing the respective 2-fold serial dilu-
tions of the compounds for 7 days, after which the clarified supernatant of four
replicate wells per plate was collected and pooled; 150 l was stored at	80°C for
later use in quantitative reverse transcriptase PCR (RT-PCR) to determine viral
RNA load. Each treatment condition was carried out in quadruplicate, and two
independent experiments were performed.
Antiviral assays for JEV, TBEV, and WNV were carried out in Vero-B cells in
24-well plates (5  104 cells/well). Briefly cells were cultured in MEM supple-
mented with 7% FCS, 2 mM L-glutamine, and penicillin-streptomycin. One day
after seeding, cells were infected with 100 l of the viral inoculum (at a multi-
plicity of infection of either 0.1 or 1) in the presence or absence of 10 g/ml (15
M) SA-17. Following incubation for 90 min (37°C; 5% CO2), cultures were
washed twice with Hanks balanced salt solution (HBSS) after which 1 ml fresh
medium either supplemented or not with 10 g/ml (15 M) SA-17 was added to
the wells. Cells were further incubated at 37°C (medium with compound was
refreshed at days 3 and 5 postinfection). At various time points p.i., supernatants
were harvested and stored at 	80°C for later use in quantitative RT-PCR.
Time-of-drug-addition assay. One day prior to infection, 2 104 BHK-21 cells
were seeded in a tissue culture-treated white-view 96-well plate. The next day,
cells were infected with 2 105 PFU/well of dengue reporter virus. After 1 h, the
virus inoculum was replaced by assay medium. SA-17 at concentrations of 0.1, 1,
or 10 g/ml (0.15, 1.5 or 15 M) was added to the assay medium either at 0 (i.e.,
together with the virus) or at 1, 2, 4, 6, 8, 10, or 12 h postinfection. Luciferase
activity was measured at 24 h p.i. using the Renilla luciferase assay system.
Luciferase activity of treated, infected cells was compared to that of untreated,
infected cells.
Real-time RT-qPCR. Total RNA was extracted from 150 l of cell culture
supernatant using the NucleoSpin RNA virus kit according to the manufacturer’s
protocol (Macherey-Nagel, Du¨ren, Germany) or using an EZ1 robot (Qiagen) in
the case of JEV, TBEV, and WNV. The sequences of the TaqMan primers
(DENV-For, DENV-Rev, MODV-For, MODV-Rev, YFV-For, YFV-Rev, JEV-
For, JEV-Rev, TBEV-For, TBEV-Rev, WNV-For, and WNV-Rev) (see Table
S1 in the supplemental material) and TaqMan probes (DENV-Probe, MODV-
Probe, YFV-Probe, JEV-Probe, TBEV-Probe, and WNV-Probe) (see Table S1)
were selected from nonstructural gene 3 (NS3), NS5, or the 3
 UTR of the
respective flaviviruses using Primer Express software (version 2.0; Applied Bio-
systems, Lennik, Belgium). The TaqMan probe was fluorescently labeled with
6-carboxyfluorescein (FAM) at the 5
 end as the reporter dye and with minor
groove binder (MGB) or tetramethylrhodamine (TAMRA) at the 3
 end as the
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quencher (see Table S1). One-step, quantitative RT-PCR (RT-qPCR) was per-
formed essentially as described earlier (1). For absolute quantification, standard
curves were generated using 10-fold dilutions of template preparations of known
concentration (PCR product using primers DENV-For and DENV-Rev, cloned
into a TOPO vector using the TOPO TA cloning kit [Invitrogen]). Data are
expressed as the percentage of untreated virus control, and log reduction values
are calculated. The detection limit of the RT-qPCR in this experimental setup
was 111 RNA copies/ml for YFV (30), 200 copies for DENV, and 6,016 copies
for MODV.
Flow cytometric analysis. C6/36 mosquito cells (4  106 cells) were seeded in
25-cm2 tissue culture flasks and allowed to proliferate for 3 days. Prior to
infection, all four serotypes of DENV (2  106 IU) were separately incubated
with or without SA-17 (ranging from 0.5 to 10 g/ml [0.77 to 15 M]) for 1 h at
37°C. C6/36 cells were then infected with the virus-compound mixtures for 2 h at
28°C, after which the infection medium was replaced with MEM containing 2%
FCS. At day 3 p.i., flow cytometric analysis was performed essentially as de-
scribed previously (1). In short, cells were fixed and permeabilized with Cytofix/
Cytoperm fixation/permeabilization solution (Becton Dickinson, Erembodegem,
Belgium) for 20 min at 4°C and rinsed with Perm/Wash buffer (Becton Dickin-
son). Next, cells were subsequently stained with anti-dengue virus complex di-
rected against the prM protein of all dengue virus serotypes (clone D3-2H2-9-21;
Chemicon International/Millipore, Billerica, MA) for 30 min at 4°C and second-
ary phycoerythrin (PE)-conjugated goat F(ab
)2 anti-mouse immunoglobulins
(M30004-1; Caltag Invitrogen, Carlsbad, CA) for 30 min at 4°C. Cells were
washed and analyzed using a FACSCalibur flow cytometer equipped with
CellQuest software (BD, San Jose, CA). The percentage of DENV-infected cells
was determined by subtracting the mean fluorescence of intensity (MFI) of the
background staining from the MFI of each sample. EC50s were obtained as
described above.
Virucidal assay. Virus stocks (5  104 PFU [DENV or YFV-17D]; 1  106
PFU [DENV or YFV-17D]; 5  106 PFU [YFV-17D]) were preincubated for
various periods of time at 37°C in the presence of various concentrations of
SA-17, doxorubicin, or an equivalent volume of the solvent (1% dimethyl sul-
foxide [DMSO] in culture medium; negative control). Following this incubation,
the virus-compound mixture was serially diluted (10- to 31,250-fold for DENV
and 60- to 187,500-fold for YFV-17D) and used to infect Vero-B cells (5  105
cells/well in a 6-well plate). Cultures were incubated for 2 h, after which they
were rinsed three times with assay medium and overlaid with a solution contain-
ing 0.5% Avicel (a codried blend of microcrystalline cellulose and sodium car-
boxymethylcellulose [FMC BioPolymer, Brussels, Belgium]) and assay medium
at a ratio of 1:1 (36). One week later, the Avicel/MEM solution was removed,
cells were washed (PBS), fixed, and stained with 1% methylene blue solution,
and the number of plaques was counted.
In a separate experiment, YFV-17D (1  106 PFU) was incubated in the
absence or presence of various concentrations of SA-17 (0.1 to 10 g/ml [0.15 to
15 M]). To one-third of the samples, 0.5 l RNase A (4 mg/ml; Promega) was
added to the reaction mixture, whereas in yet another third of the samples, 1 l
RNase A was added. All samples were subjected to incubation for 1 h at 37°C,
after which viral RNA was extracted (using the NucleoSpin RNA virus kit) in the
presence of proteinase K (0.4 mg; Promega) and detected via RT-qPCR. As a
positive control, YFV-17D was incubated with proteinase K for 1 h at 37°C.
Subsequently, RNase A together with phenylmethanesulfonyl fluoride (PMSF; 5
mM; Sigma-Aldrich) was added to the mixture, which was incubated for another
30 min at 37°C. PMSF was added to the reaction to inhibit proteinase K activity.
Viral RNA extraction and quantification were performed as described above.
Dengue virus subgenomic replicon assay. BHK-Rep-Pac-LUC cells were
seeded at a density of 1  104 cells/well in a tissue culture-treated white-view
96-well plate (Perkin-Elmer). The next day, medium was replaced by assay
medium containing various concentrations of SA-17 or doxorubicin (concentra-
tions ranged from 0.1 to 5 g/ml [0.15 to 7.7 M and 0.18 to 9.2 M, respec-
tively]). After 72 h, luciferase activity was measured using the luciferase assay
system according to the manufacturer’s protocol (Promega). Luciferase activity
was compared to that of untreated replicon cells. The cytotoxic effect of the
compounds on BHK-Rep-Pac-LUC cells was evaluated with parallel cultures.
Ribavirin was included as a replication inhibitor for comparative reasons. The
inhibitory effect of the compounds on luciferase activity was adjusted for inhib-
itory effects on cell proliferation.
Docking experiments. Docking of SA-17 in the prefusion form of the DENV-2
E glycoprotein (PDB code 1oke) (39) was performed using Autodock 4.0 (43). A
docking zone of a 50-angstrom cube situated around Ile-270 in the -OG
(n-octyl--D-glucoside) (40) binding cleft of the dengue virus E glycoprotein
dimer was defined. The SA-17 conformation was obtained from the Dundee
PRODRG2 server (55). Gasteiger charges were added to ligand and protein;
only polar H was kept for the docking experiments. All default docking param-
eters were used, except the number of dockings was increased to at least 50, and
docking runs were repeated three times. The final selection was based on the low
score and as many possible interactions with the surrounding amino acids (hy-
drogen bonds and hydrophobic interactions).
RESULTS
SA-17 is a selective inhibitor of flavivirus replication. Doxo-
rubicin was identified as an in vitro inhibitor of DENV-2 NGC
(EC50  0.67  0.37 g/ml [1.2  0.68 M])- and YFV-17D
(EC50  0.32  0.01 g/ml [0.59  0.02 M])-induced CPE
formation (Table 1; Fig. 1A and B). However, doxorubicin also
exhibited rather pronounced cytotoxic activity (CC50  13 
0.7 g/ml [24 1.3 M]) in the host (Vero-B) cell (Fig. 1A and
B). This finding prompted the evaluation of the antiviral ac-
tivity of a selection of doxorubicin analogues. The squaric
amide ester SA-17 was found to be roughly twice as effective as
the parent compound in inhibiting DENV-2 NGC replication
(EC50 0.34 0.20 g/ml [0.52 0.31 M]) (Fig. 1C) but was
less effective than the parent compound with YFV-17D repli-
cation (EC50  3.1  1.0 g/ml [4.8  1.5 M]) (Fig. 1D). In
addition, SA-17 proved markedly less cytostatic (CC50  28 
2.7 g/ml [43  4.1 M]) than the parent compound.
The antiviral activity (2 log reduction) was confirmed in a
virus yield assay using DENV-2 NGC (EC50 DENV  0.76 
0.60 g/ml [1.2  0.92 M]) (Fig. 1E) and YFV-17D
(EC50 YFV  1.9  1.2 g/ml [2.9  1.8 M]) (Fig. 1F) and by
means of flow cytometry (EC50 DENV-2  0.5 g/ml [0.77
M]; Table 2). SA-17 also inhibited the replication of an in-
fectious, full-length dengue reporter virus expressing Renilla
luciferase in a dose- and time-dependent manner (EC50 
3.6  1.6 g/ml [5.5  2.5 M] at t  48 h p.i.) (data not
shown). In addition, SA-17 was found to inhibit the replication
of DENV-1 (EC50  8.3  1.4 g/ml [12  2.1 M]) and
DENV-3 (EC50  1.1  0.5 g/ml [1.7  0.77 M]) in insect
cells, but not that of DENV-4 (EC50  10 g/ml [15 M])
(Table 2). SA-17 also inhibited the replication of the murine
flavivirus Modoc virus (EC50  1.9  0.3 g/ml [2.9  0.46
M]) (Table 2) but proved inactive against other flaviviruses
(i.e., JEV, TBEV, WNV [EC50  10 g/ml (15 M)]) (data
not shown) or a selection of other viruses (with either a DNA
FIG. 1. Dose-response curves for doxorubicin and SA-17 against DENV and YFV. Cytotoxic (white diamonds) and antiviral effect (black bars)
of doxorubicin against DENV-2 NGC (A) and YFV-17D (B). Cytotoxic and antiviral effect of SA-17 against DENV-2 NGC (C and E) and
YFV-17D (D and F). Cytotoxic and antiviral effect of the positive-control compound ribavirin against DENV-2 NGC (G and H). Antiviral activity
was determined by means of a CPE reduction assay using MTS/PMS (A, B, C, D, and G) and RT-qPCR (E, F, and H). Antiviral data are expressed
as percentage of the cytopathic effect (CPE) of untreated virus control (VC). Mean log reduction values (0) are depicted in italics at the top of
each bar (E, F, and H). Cytotoxic data are expressed as percentage of cell growth of untreated control. Data are mean values  standard deviation
(SD) for at least three independent experiments.
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or RNA genome and either enveloped or not (i.e., coxsack-
ievirus B3, HIV-1, influenza A virus, and HSV-1 [EC50  100
g/ml (153 M)]) (data not shown).
The effect of SA-17 and doxorubicin was evaluated on the
proliferation of exponentially growing Vero-B cells during 20
consecutive passages. Doxorubicin at concentrations of 1 and
10 g/ml resulted in complete destruction of Vero-B cells from
the culture following, respectively, three and two consecutive
passages. At the same concentrations, cells that had been cul-
tured with SA-17 proliferated efficiently after 20 passages of
drug pressure (Fig. 2).
Time-of-drug-addition studies. To examine which stage of
the viral replication cycle (i.e., the complete process from virus
binding to release) is affected by SA-17, a time-of(-drug)-ad-
dition experiment was carried out. Various concentrations of
SA-17 were added to dengue reporter virus-infected cells ei-
ther at the time of infection or at several time points postin-
fection. At 24 h postinfection, luciferase activity was quantified
and compared to that of untreated, infected cells. Infection in
the presence of 1 or 10 g/ml (1.5 or 15 M) SA-17 resulted in,
respectively, 41% or 98% inhibition of virus replication (Fig.
3B). When the compound was added at later stages postinfec-
tion, SA-17 failed to efficiently inhibit viral replication. This
provides evidence that SA-17 either interferes with the earliest
stages of the viral replication cycle (i.e., virus attachment
and/or virus entry) or, alternatively, exerts a virucidal action.
SA-17 inhibits the infectivity of DENV and YFV particles.
High-titer stocks of DENV-2 NGC or YFV-17D were prein-
cubated at 37°C with either 1 or 10 g/ml (1.5 or 15 M) SA-17
for various periods of time, after which serial dilutions of the
virus-compound mixture were used to infect cell cultures. Pre-
incubation of a virus preparation of 5  104 PFU with 1 g/ml
(1.5 M) SA-17 inhibited subsequent DENV- and YFV-in-
duced plaque formation by 90% (1 log reduction) (Fig. 4D
and E). Complete inhibition of plaque formation was observed
when the virus stocks were incubated with SA-17 at concen-
trations of 5 g/ml (7.7 M) or higher (3 log reduction) (Fig.
4D and E). EC50s for inhibition of virus infectivity by SA-17
following preincubation were calculated to be 0.17  0.01
g/ml (0.26  0.02 M) for DENV-2 and 0.15  0.06 g/ml
(0.23  0.09 M) for YFV-17D. The inhibitory activity of
SA-17 was not attributable to a carryover effect of the com-
pound, since the sixth well shown in Fig. 4C (containing 0.32
ng/ml SA-17 [0.49 nM]) did not show any plaques, whereas the
first well shown in Fig. 4B (containing 0.1 g/ml SA-17 [0.15
M]) contained numerous plaques. When the titer of the viral
inoculum was 20-fold higher (1  106 PFU), SA-17 retained
about the same efficacy in this assay (EC50s of 0.25  0.04
g/ml [0.38  0.06 M] and 0.21  0.01 g/ml [0.21  0.02
M] for DENV-2 and YFV, respectively) (Fig. 4D and E).
Preincubation of 5  106 PFU of a YFV-17D stock (100-fold-
higher titer) with 10 g/ml (15 M) SA-17 resulted in 98%
inhibition of plaque formation (1.7 log reduction) (Fig. 4E).
Doxorubicin proved markedly less potent than SA-17 in this
assay. When 5  104 PFU of DENV-2 stock was preincubated
with 10 g/ml (18 M) doxorubicin, a maximum of 73% re-
duction in plaque formation was obtained (0.6 log reduction)
(Fig. 4F).
Subsequently, the time dependency of the virus-inactivating
activity of SA-17 was studied (Fig. 4G). A 50% inhibition of
plaque formation (0.4 log reduction) was observed when YFV-
17D stock was preincubated with 10 g/ml (15 M) SA-17 for
5 min. Complete inhibition of YFV infection of the cells (2.4
log reduction) was obtained following preincubation with 5
g/ml (7.7 M) SA-17 for periods of 45 min and longer.
To study whether the inhibitory effect of SA-17 was the
result of a direct virucidal activity, YFV-17D was incubated for
1 h with various concentrations of SA-17 in the absence or
presence of RNase A. Next, viral RNA was extracted and
TABLE 2. Effect of SA-17 on the replication of selected flaviviruses
Virus
EC50 (g/ml)a,b
CPE-based RT-qPCR Antigen expression
Dengue 1 Djibouti D1/H/IMTSSA/98/606 NT NT 8.3  1.4 (12  2.1)
Dengue 2 New Guinea C 0.34  0.20 (0.52  0.31) 0.76  0.60 (1.2  0.92) 0.5 (0.77)
Dengue 3 H87 NT NT 1.1  0.5 (1.7  0.77)
Dengue 4 Dak HD 34 460 NT NT 10 (15)
Yellow fever virus 17D 3.1  1.0 (4.8  1.5) 1.9  1.2 (2.9  1.8) NT
Modoc NT 1.9  0.3 (2.9  0.46) NT
a Data are expressed in g/ml (M in parentheses) and are mean values  standard deviations from at least two independent experiments. NT, not tested.
b EC50 of SA-17 for inhibition of DENV-2 NGC and YFV-17D replication was determined with Vero-B cells. EC50 of SA-17 for inhibition of MODV replication
was determined with BHK-21 cells by means of RT-qPCR. The effect of SA-17 on DENV-1, DENV-2, DENV-3, and DENV-4 antigen expression was determined with
C6/36 mosquito cells by means of flow cytometry.
FIG. 2. The effect of SA-17 and doxorubicin on exponentially grow-
ing Vero-B cells. Cells were seeded in the absence or presence of
either 1 (F) or 10 (E) g/ml (1.5 or 15 M) SA-17 or 1 (Œ) or 10 (‚)
g/ml (1.8 or 18 M) doxorubicin for 20 passages. The cell number
was determined at 7 days postseeding (after every passage). Data are
expressed as percentage of cell growth of untreated cultures and rep-
resent mean values  SD for at least three independent experiments.
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quantified by means of RT-qPCR. Viral RNA levels were
identical for both RNase-treated and RNase-untreated sam-
ples (data not shown). In contrast, the positive-control sample
(i.e., YFV treated with proteinase K and RNase A in the
presence of PMSF) showed a 95% reduction of viral RNA load
(data not shown). Together, these data and the central exper-
iment demonstrate that SA-17 does not disrupt virion integrity.
SA-17 does not inhibit DENV subgenomic replicon replica-
tion. If SA-17 exerts its activity at a very early step, the com-
pound may be expected not to inhibit the replication of a
DENV subgenomic replicon. To test this hypothesis, DENV
subgenomic replicon-containing cells (BHK-Rep-Pac-LUC)
were cultured in the presence of various concentrations (0.1 to
5 g/ml) of SA-17 (0.15 to 7.7 M) or doxorubicin (0.18 to 9.2
M). Replication of the subgenomic replicons was not signif-
icantly impaired in the presence of 0.1 to 5 g/ml (0.18 to 7.7
M) SA-17 (Fig. 5B). In contrast to SA-17, ribavirin, which
was included as a replication inhibitor, clearly reduced the
replication of the dengue virus replicons (Fig. 5C) (79% and
68% inhibition of luciferase activity at a concentration of 1 and
5 g/ml [4.1 and 21 M], respectively). Thus, SA-17 does not
inhibit DENV RNA replication.
Long-term antiviral pressure with SA-17 does not result in
the selection of drug-resistant variants. It was studied whether
DENV-2 or YFV-17D drug-resistant variants could be gener-
ated following long-term selective pressure with various con-
centrations of SA-17. Even following 30 passages in the pres-
ence of various concentrations of the compound (0.1 to 20
g/ml [0.15 to 31 M]), no shift in sensitivity/the EC50 was
noted.
Docking of SA-17. Since SA-17 was shown to decrease viral
infectivity when preincubated with the virus without being viru-
cidal, whether the compound has the potential to interact with
the prefusion form of the DENV E glycoprotein was studied by
means of a docking algorithm. As depicted in Fig. 6A and B,
SA-17 is predicted to dock in the -OG binding cleft of the
dengue virus E protein. SA-17 may interact predominantly
with amino acid residues Ala-50, Tyr-137, and Gln-200 through
hydrogen bonds (Fig. 6A). Other nonligand residues that
might be involved in hydrophobic interactions are Thr-48, Pro-
53, Lys-128, Leu-135, Phe-193, Leu-198, Ala-205, Ile-270, Gln-
271, Thr-280, and Gly-281 (Fig. 6A).
DISCUSSION
A safe and efficient anti-dengue virus drug (or combination
of drugs) may have the potential to (i) reduce the total number
of people developing dengue fever, dengue hemorrhagic fever,
and dengue shock syndrome, in particular during epidemic
situations in areas where dengue virus is endemic, and (ii)
provide protection for people who travel to and through re-
gions where dengue virus is endemic.
The anthracycline doxorubicin is an antineoplastic antibiotic
from Streptomyces peucetius (34). The drug exhibits broad-
spectrum antitumor activity and is used for the treatment of
cancer, in particular solid tumors (2, 13, 44, 46, 50). Doxoru-
bicin was reported to elicit antiviral activity in vitro, including
against HIV, herpes simplex virus, Rauscher leukemia virus,
and avian myeloblastosis virus (3, 21, 22, 48). On the other
hand, however, doxorubicin was reported to cause reactivation
of latent viruses, including herpes simplex virus and the Ep-
stein-Barr virus (17, 18, 54). Our aim was to study whether
doxorubicin inhibits the in vitro replication of flaviviruses and,
if so, whether analogues can be developed that are more po-
FIG. 3. Time-of-addition study using dengue reporter virus. (A) Genome organization of an infectious, full-length dengue reporter virus
expressing Renilla luciferase. White boxes represent the proteins encoded by DENV-2 16681, both structural (C, prM, and E) and nonstructural
proteins (NS1 to NS5). The Renilla luciferase coding sequence (LUC; black box) is fused to the encephalomyocarditis virus internal ribosome entry
site (IRES) (42). UTR, untranslated region. (B) The effect of time-of-(drug-)addition on the antiviral activity of SA-17 using an infectious,
full-length dengue reporter virus. Infected BHK-21 cells were treated with 0.1 (Œ), 1 (F), or 10 (E) g/ml (0.15, 1.5 or 15 M) SA-17 at various
time points p.i., starting at 0 h p.i. Luciferase activity was measured at 24 h p.i. Luciferase activity of treated, infected cells was compared to that
of untreated, infected cells and expressed as percentage of inhibition. Data are mean values  SD for at least three independent experiments.
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tent/selective. We indeed observed that doxorubicin exhibits in
vitro antiviral activity against the flaviviruses DENV-2 and
YFV-17D. However, and as expected, doxorubicin exerts pro-
nounced cytotoxic and cytostatic activity. To study whether the
antiviral activity extended to analogues and, if so, if the anti-
viral activity could be dissected from the cytotoxicity, the anti-
flavivirus activity and effect on the uninfected host cell of a
number of analogues of doxorubicin (62) were evaluated. In
particular, the SA-17 derivative, which carries a squaric acid
amide ester moiety at the carbohydrate (-L-daunosaminyl)
group, was found to efficiently inhibit DENV-2 replication as
well as replication of DENV-1, DENV-3, YFV-17D, and the
murine flavivirus Modoc virus. The compound proved inactive
against DENV-4, JEV, WNV, and TBEV as well as against a
number of viruses belonging to other families. SA-17 proved
markedly less cytotoxic and cytostatic than the parent com-
pound doxorubicin. Time-of-drug-addition studies revealed
that the compound acts at a stage that coincides with the early
events of the flavivirus replication cycle. Preincubation of the
virus with SA-17 (e.g., 5 g/ml [7.7 M] for 45 min) was able
to completely abolish viral infectivity. In the case that SA-17
acts at the level of the viral particle or at a very early stage of
the viral replication cycle, it may be assumed that the com-
pound will have no effect on intracellular RNA replication.
Indeed, SA-17 did not inhibit the replication of a subgenomic
DENV replicon, whereas the replication inhibitor ribavirin
did. The question remains as to precisely how SA-17 interacts
with the flavivirus particle. It is rather unlikely that the com-
pound targets the lipid bilayer of the virus, since other unre-
lated enveloped viruses (i.e., HIV-1 and influenza virus) are
not sensitive to SA-17. A direct virucidal effect was also ex-
cluded since incubation of the virus with SA-17 did not result
in degradation of viral RNA by subsequent RNase treatment.
An alternative explanation may be that SA-17 interacts in a
specific manner with the envelope glycoprotein and thereby
hinders proper functioning of this glycoprotein. This was re-
cently also suggested for two tetracycline derivates, i.e., rolitet-
racycline and doxycycline, based on computational approaches
(73). The flavivirus E glycoprotein is involved in virus attach-
ment and entry, for which several conformational rearrange-
ments are needed. Both tetracycline derivates are believed to
putatively block the conformational change of the E protein
during membrane fusion and, thereby, viral entry (73). Like-
wise, and given the structural relationship between tetracy-
clines and the anthracycline doxorubicin (i.e., anthracyclines
consist of a tetracycline moiety), SA-17 may interfere with the
FIG. 4. Effect of SA-17 on viral infectivity. DENV-2 NGC (5  104 PFU) was preincubated in the absence (	) (A) or presence of 1 (1.5 M)
(B) or 10 g/ml (15 M) SA-17 (C). Cells in 6-well plates were infected with serial dilutions (ranging from a 10 to a 31,250 dilution
corresponding to wells 1 to 6) of preincubated virus with or without compound. Effect of SA-17 on DENV-2 NGC (D) and YFV-17D (E and G)
using an inoculum of 5  104 PFU (black bars), 1  106 PFU (hatched bars), or 5  106 PFU (gray bars). Effect of doxorubicin on DENV-2 NGC
(F). Virus with or without compound was preincubated for either 1 h (D, E, and F) or various periods of time (G) at 37°C. Data are expressed
as percentage of inhibition of plaque formation and represent mean values  SD for at least three independent experiments. Mean log reduction
values (0) are depicted in italics at the top of each bar.
FIG. 5. Effect of SA-17 on dengue virus subgenomic replicon replication. (A) Genome organization of dengue virus subgenomic replicons that
harbor only the NS genes of dengue virus 2 NGC (23). The puromycin N-acetyltransferase (PAC) gene together with the firefly luciferase (LUC)
expression cassette was inserted upstream of the NS genes. Effect of SA-17 (B) and the reference compound ribavirin (RBV) (C) on dengue virus
subgenomic replicon replication. Various concentrations of SA-17 or RBV were added to the culture medium of replicon cells (BHK-Rep-Pac-
LUC), and luciferase activity was measured after 72 h. Luciferase activity was compared to that of untreated replicon cells and expressed as
percentage of inhibition. The inhibitory effect of SA-17 and RBV on luciferase activity was adjusted for inhibitory effects on cell proliferation. Data
are mean values  SD for at least three independent experiments.
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conformational change of the E protein that is essential for
DENV entry and, eventually, infection of the host cell. Dock-
ing experiments revealed that SA-17, like rolitetracycline and
doxycycline, fits into the hydrophobic detergent-binding pocket
of the E protein. Interestingly, among the residues possibly
involved in binding SA-17 are those reported to be critical in
membrane fusion during virus entry, namely, Thr-48, Glu-49,
Ala-50, Lys-51, and Gln-52 (39, 40). Even following 20 pas-
sages of culturing in the presence of suboptimal concentrations
of SA-17, we were unable to select for drug-resistant variants.
Identification of mutations responsible for the drug-resistant
phenotype should have allowed the identification of a viral
factor as the antiviral target, such as the E protein. The reason
for this failure might be that 20 passages of antiviral pressure
are too short to select for resistant virus against this particular
compound and, thus, that the barrier to resistance is high. Even
antiviral molecules that target a cellular factor, such as the
cyclophylin-binding compound Debio 025, which is a potent
inhibitor of HCV replication (11, 47), may result in mutations
in the viral genome that explain the antiviral resistance (L.
Coelmont, X. Hanoulle, U. Chatterji, C. Berger, J. Snoeck, M.
Bobardt, P. Lim, I. Vliegen, J. Paeshuyse, G. Vuagniaux, R.
Bartenschlager, P. Gallay, G. Lippens, and J. Neyts, submitted
for publication). We continue our effort to select for drug-
resistant variants.
It is intriguing that SA-17 seems to lack activity against
dengue virus serotype 4. We have at present no explanation for
this observation. Sequence alignment and phylogenetic tree
analysis of the dengue virus E proteins, on which DENV se-
rotype classification is based, demonstrate that DENV-4 is the
most divergent dengue virus serotype (16, 27, 68). Likewise, we
can as yet not explain the lack of activity against JEV, TBEV,
and WNV. However, as is the case for DENV-4, sequence
divergence at the position where the inhibitor interacts with
the virus likely explains this difference.
Challenges for future studies will be to (i) confirm that
SA-17 indeed interacts with the viral E glycoprotein, (ii) eval-
uate the antiviral activity of SA-17 in DENV/mouse models
(19, 53, 57, 58), and (iii) improve antiviral potency against
flaviviruses on the one hand and reduce or even eliminate any
residual cytotoxic/cytostatic activity on the other hand (i.e.,
increase activity and selectivity) through lead optimization pro-
cedures. Drugs with properties like those of SA-17 may be
effective in lowering circulating infectious virus titers during
FIG. 6. Results of docking calculations. (A) A ligplot interaction map of docked SA-17 in the -OG binding pocket in one molecule ([indicated
by “(A)”] of the dengue virus envelope dimer. (B) Representation of the SA-17 molecule located in the -OG binding site. One molecule of the
E glycoprotein dimer is represented by a blue surface; the other one is represented by a yellow surface. The SA-17 molecule is displayed in green;
nonligand residues are exhibited in gray. The formation of hydrogen bonds is shown by a green dashed line. Docking results were generated using
Ligplot software (A) or bobscript, molscript, and raster3D (B) (14, 24, 38, 65).
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viremia. DENV viral load positively correlates with the severity
of clinical disease (32, 64, 67). Safe drugs that prevent infection
of cells may, either alone or in combination with, for example,
replication inhibitors, reduce the number of patients who de-
velop significant clinical disease. Reducing viral loads may not
only prevent clinically significant disease in individuals but may
also contribute to epidemic control. Mosquitoes are remark-
ably resistant to dengue virus infection by the oral route and
require high titers (105 to 107 particles/ml) in human blood to
become infected (41). Any reduction in viral load brought
about by drug treatment will therefore reduce the chance of
transmission of DENV between humans, which may play a
crucial role in the future control of dengue epidemics.
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